CEO sells $7.4M as JP Morgan lifts target above $166

BNY gained 1.3% over the past week, a touch behind the median 1.7% advance across its closest custody and asset-management peers, with GS up 2.2% and MS gaining 2.7% while IVZ was the only name in the group to fall.

The most arresting data point this week is not in the lending market or the options chain. CEO Robin Vince sold 50,000 shares across October 26 and 27 for a combined $7.4 million in open-market disposals, none of which were filed under a 10b5-1 pre-arranged plan. That matters: a discretionary sale by a chairman-and-CEO carries far more signal weight than a scheduled one. Senior Executive VP Jose Minaya added further selling over the same two days, though those trades were plan-governed and total just over $520,000. Net insider activity across the 90-day window runs to roughly -$13.9 million, with 92,360 shares sold on balance.

Options positioning has stayed elevated but has not broken to new extremes. The put-call ratio closed at 1.92 on October 30, just below the 1.93 52-week high set on October 19 and 1.4 standard deviations above its 20-day average of 1.82. The previous ORTEX note flagged the same cluster of readings above 1.85 stretching back to October 19 as the longest such run of the year. That cluster has held. Borrow conditions, by contrast, remain wholly unremarkable: availability is effectively unlimited with far more shares in the lending pool than have been borrowed, cost to borrow is 0.35%, and short interest is only 1.2% of the free float, down roughly 16% over the past month.

The Street's posture is mixed but tilting constructive on the margin. JP Morgan raised its target to $166.50 from $161 on October 30, maintaining an Overweight rating, making it the most recent and the most bullish of the active recommendations. Other analysts have been more cautious: Citigroup trimmed its target twice in October, settling at $157 with a Neutral, while Truist cut from $172 to $165 but kept a Buy. The consensus sits at Hold, with a mean target of $164, implying about 11% above the current price of $147.11. The PE stands at 14.6x, up a fraction over 30 days, and the price-to-book is 2.36x. Factor scores are solid on days-to-cover (84th percentile) and dividend (77th percentile), though analyst recommendation dispersion sits near the midpoint at 49, reflecting the genuine split of opinion on the stock.

The alt data register carries one fact worth noting. BNY's Q2 2026 buyback spend came in at $1.1 billion, the largest second quarter on record going back to 2009. Remaining buyback authorisation has fallen 38% versus Q4 of last year, consistent with that pace of deployment. The alt data layer carries no measured leading indicators for BNY's reported figures, so the buyback data is context rather than a forward signal.

What to watch next: whether CEO Vince's discretionary selling continues into November, and whether the put-call ratio finally breaks back toward its 20-day average as the January 15 earnings date moves into view.